ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

NCI SBIR Offers $10 million in 10 Awards

February 18, 2011

New CREG Announcements Made By NCI

October 3, 1975

ICCCR Issues RFP For Cancer Risk Scale

March 6, 1992

Bunn Says ASCO Is “Strong, Diverse, Respected, Growing”

June 6, 2003

In Brief: Bruce Chamber Is DeVita’s Choice as Permanent Director Of DCT; Six New RCDAs Funded In FY 1982

June 11, 1982

Ominous Note: Magnuson Hints Senate May Cut NCI Budget 5% Under President’s 1980 Request

March 9, 1979